Participated · Equity · Apr 2026

ADEL develops therapeutics targeting central nervous system disorders and advances antibody candidates through clinical development. Its notable programs include ADEL-Y01, a tau antibody candidate that was licensed out to Sanofi in a deal valued up to $1.04 billion with an $80 million non-refundable upfront payment. The company is advancing follow-on candidates ADEL-Y04 (ApoE4-targeting antibody) and ADEL-Y03 (β2-microglobulin-targeting antibody) and aims to accelerate their clinical timelines. ADEL intends to strengthen partnerships with domestic and international CNS specialists and further develop proprietary technology platforms. The company cites global business achievements and investor support as validation of its pipeline value. Management plans to complete a KOSDAQ technology special listing within the year and deploy the newly secured funds to deliver early pipeline development results.

Participated · Series B · Feb 2026

Galux leverages its proprietary GaluxDesign platform, which integrates deep-learning with biophysical principles, to design high-affinity antibodies and other proteins from scratch. The platform has already produced antibodies whose AI-predicted structures align closely with cryo-EM data, validating its precision and generalizability. Galux is expanding the technology to harder target classes such as GPCRs and ion channels while tightly coupling AI modeling with wet-lab feedback to speed iteration. The company has formed co-development partnerships with Celltrion, LG Chem, and most recently Boehringer Ingelheim to broaden its pipeline and global reach. Proceeds from the latest financing will enhance the AI engine, grow R&D infrastructure, and advance proprietary programs into preclinical validation. Since its 2022 $18 million Series A, Galux has hit multiple R&D and business milestones, helping it secure the follow-on funding. Cumulatively, the company has raised $47 million to date.

Participated · Series A · Oct 2024

VESSL AI provides an MLOps platform that automates model training, real-time deployment, pipelines, and GPU cluster optimization. The platform targets companies building custom large language models and vertical AI agents, and emphasizes a hybrid multi-cloud approach using spot instances to reduce GPU expenses by up to 80%. VESSL offers four main features: VESSL Run, VESSL Serve, VESSL Pipelines, and VESSL Cluster. The company has over 2,000 users and 50 enterprise customers, including Hyundai, LIG Nex1, TMAP Mobility, Yanolja, Upstage, ScatterLab and Wrtn.ai. It has strategic partnerships with Oracle and Google Cloud in the U.S. and operates with about 35 staff across South Korea and a San Mateo office. The startup was founded in 2020 and will use the new funding to accelerate development of its infrastructure.

Participated · Series A · Sep 2024

Mediwhale develops AI-driven retinal imaging analysis tools that predict cardiovascular risk from a single eye image, marketed under names including Dr. Noon CVD. The company is focused on commercializing those AI biomarkers and expanding partnerships with imaging hardware vendors such as iCare. Mediwhale is actively pursuing FDA De Novo clearance to access the U.S. market and has publicly stated plans to prepare for a public listing, targeting KOSDAQ in 2027 while positioning for a broader U.S. listing narrative. Financially, the firm has raised roughly ₩51.2 billion (about $34M) to date, most recently securing ₩20 billion in a Series C. The company emphasizes scaling global commercialization and regulatory readiness as near-term priorities.

Participated · Series C · Jun 2024

Nota AI develops on-device generative AI optimization and lightweighting technology through its NetsPresso platform, enabling AI models to run directly on edge devices. The company has established official partnerships with global tech firms including NVIDIA, ARM, Intel, STMicroelectronics and Renesas and holds contracts to provide optimization technology to leading AI semiconductor companies. Founded in 2015 and based in Seoul, Nota AI has expanded its customer base domestically and internationally and has received early backing from Naver D2SF. Cumulative funding since inception is approximately $42.6 million, and the company reports strong near-term revenue momentum—expecting first-half 2024 sales to exceed total 2023 sales and forecasting a 300% sales increase for 2024 versus the prior year. With the new funding, Nota AI plans to recruit top AI optimization talent, deepen collaborations with global AI semiconductor players, and extend its optimization technology into industries such as robotics and mobility. The company is preparing for an IPO in early 2025 with Mirae Asset Securities as lead underwriter. Nota is a compressed AI solutions and software optimization platform founded in 2015 that focuses on B2B and B2G markets. Its main product, NetsPresso, is an automatic model compression platform that downsizes computer vision models for edge and low-spec device deployment. Nota’s AI technology is applied in intelligent transportation, facial recognition, and security and surveillance through solutions such as Driver Monitoring System, Driver Authentication, and Smart Access Control System. In November 2021 Nota raised $14.7M in a Series B, bringing its total funding to $23M. The company plans to expand its global business, enhance its AI optimization technology, and strengthen its R&D team by recruiting additional top-tier talent. Nota is headquartered in Seoul, South Korea.